You are here: Welcome to the MPKB » Welcome to the MPKB » Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:mp [05.26.2019] – [Response in 5 diagnoses] sallieqhome:mp [05.26.2020] – [Laboratory tests] sallieq
Line 3: Line 3:
  
 ====== Marshall Protocol ====== ====== Marshall Protocol ======
 +
 +<relatedarticles> [[home:starting:usingforum:home_help_using_forums:a_a_href|5 key elements of MP]] </article>
  
 This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians.  Many of the topics covered here are reviewed in greater depth throughout the Knowledge Base.  This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians.  Many of the topics covered here are reviewed in greater depth throughout the Knowledge Base. 
Line 125: Line 127:
 If these markers indicate dysfunction sustained for more than several months, we advising using [[home:mp:managing_immunopathology|one or more methods]] to lower immunopathology levels. If these markers indicate dysfunction sustained for more than several months, we advising using [[home:mp:managing_immunopathology|one or more methods]] to lower immunopathology levels.
  
 +**//See also//** [[home:diseases:kidney_disease|Kidney information]]
  
  
Line 254: Line 257:
 ===== Data ===== ===== Data =====
  
-[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]+[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]  (extract below)
  
 [[home:food:aim_health:aging|Olmesartan research]] [[home:food:aim_health:aging|Olmesartan research]]
home/mp.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.